

Therapeutic Hypercapnia Is Not Protective in the *in vivo* Surfactant-Depleted Rabbit Lung

SHARADINDU RAI, DOREEN ENGELBERTS, JOHN G. LAFFEY, CHARLES FREVERT, OSAMU KAJIKAWA, THOMAS R. MARTIN, MARTIN POST, AND BRIAN P. KAVANAGH

The Lung Biology Program [S.R., D.E., J.G.L., M.P., B.P.K.] and the Department of Critical Care Medicine and Anaesthesia [J.G.L., B.P.K.], The Hospital for Sick Children; and The Interdepartmental Division of Critical Care Medicine, The University of Toronto [J.G.L., B.P.K.], Toronto, Ontario M5G 1X8, Canada; and The Department of Medicine, University of Washington, Veterans Affairs Puget Sound Health Care System, Seattle, Washington 98108, U.S.A. [C.F., O.K., T.R.M.].

ABSTRACT

Permissive hypercapnia because of reduced tidal volume is associated with improved survival in lung injury, whereas therapeutic hypercapnia—deliberate elevation of arterial P_{CO_2} —protects against *in vivo* reperfusion injury and injury produced by severe lung stretch. No published studies to date have examined the effects of CO_2 on *in vivo* models of neonatal lung injury. We used an established *in vivo* rabbit model of surfactant depletion to investigate whether therapeutic hypercapnia would improve oxygenation and protect against ventilator-induced lung injury. Animals were randomized to injurious (tidal volume, 12 mL/kg; positive end-expiratory pressure, 0 cm H_2O) or protective ventilatory strategy (tidal volume, 5 mL/kg; positive end-expiratory pressure, 12.5 cm H_2O), and to receive either control conditions or therapeutic hypercapnia (fraction of inspired CO_2 , 0.12). Oxygenation (alveolar-arterial O_2 difference, arterial PO_2), lung injury (alveolar-capillary protein leak, impairment of static compliance), and selected bronchoalveolar lavage and plasma cytokines (IL-8, growth-related oncogene, monocyte chemoattractant protein-1, and tumor necrosis factor- α) were measured. Injurious ventilation resulted in a large alveolar-arterial O_2 gradient, elevated peak airway pressure, increased protein leak, and impaired lung compliance. Therapeutic hypercapnia did not affect any of these outcomes. Tumor necrosis factor- α was not increased by mechanical stretch in any of the groups. Therapeutic hypercapnia abolished the stretch-induced increase in bronchoalveolar lavage monocyte chemoattractant protein-1, but did not affect any of the

other mediators studied. Therapeutic hypercapnia may attenuate the impairment in oxygenation and inhibit certain cytokines. Because hypercapnia inhibits certain cytokines but does not alter lung injury, the pathogenic role of these cytokines in lung injury is questionable. (*Pediatr Res* 55: 42–49, 2004)

Abbreviations

A-a O_2 , alveolar-arterial O_2 gradient
BAL, bronchoalveolar lavage
CON_{inj}, normocapnia, injurious ventilation
CON_{pro}, normocapnia, protective ventilation
CPAP, continuous positive airway pressure
 ΔP_{aw} , delta airway pressure
ETT, endotracheal tube
Fico₂, fraction of inspired carbon dioxide
Fio₂, fraction of inspired oxygen
GRO, growth-related oncogene
MCP-1, monocyte chemoattractant protein-1
Paco₂, partial pressure of arterial carbon dioxide
Pao₂, partial pressure of arterial oxygen
PEEP, positive end-expiratory pressure
TH_{inj}, therapeutic hypercapnia, injurious ventilation
TH_{pro}, therapeutic hypercapnia, protective ventilation
TNF- α , tumor necrosis factor- α
VALI, ventilator-associated lung injury
V_t, tidal volume

Mechanical ventilation is central to neonatal and pediatric critical care. Limiting V_t during mechanical ventilation in the setting of acute lung injury results in several important effects,

including elevation of P_{aco_2} (1, 2), alteration of lung inflammatory events (3), decreased duration of mechanical ventilation (4), and improved survival (5). Although the associations among these effects are clear, the mechanistic relationships are uncertain. Lung stretch is associated with a complex series of pulmonary and systemic events, including neutrophil recruitment (6) and release of inflammatory prostanoids (7, 8) and cytokines (9–11) as well as morphologic injury (6, 12).

Alterations in CO_2 tension may be important in this paradigm for several reasons (13). First, changes in P_{aco_2} are

Received October 8, 2002; accepted July 29, 2003.

Correspondence: Brian P. Kavanagh, M.D., Department of Critical Care Medicine, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada; e-mail: brian.kavanagh@sickkids.ca

Supported by The Canadian Institutes of Health Research. Dr. Kavanagh is the recipient of a PREA award (Ontario Ministry of Science and Technology) and a New Investigator Career Award (Canadian Institutes of Health Research).

DOI: 10.1203/01.PDR.0000098502.72182.55

inextricably linked to tidal stretch, such that reduced stretch increases P_{aCO_2} and increased stretch lowers P_{aCO_2} . The impact of reduced V_t on P_{aCO_2} can be abrogated by inversely adjusting ventilatory frequency to maintain overall alveolar ventilation. Nonetheless, some residual elevation of P_{aCO_2} is usual (2, 3, 14), resulting in the original term “permissive hypercapnia” (2). Indeed, this clinical approach, originally reported in a case series by Wung *et al.* (1), has been extended in a randomized controlled trial to neonates with hypoxemic respiratory failure (4), with improvement in short-term respiratory outcome. In any case, when stretch is altered in patients, so too is P_{aCO_2} . Second, alteration of P_{aCO_2} has important effects on gas exchange (15, 16) because hypocapnia worsens oxygenation whereas hypercapnia may enhance tissue oxygenation. Third, elevated CO_2 can exert direct antiinflammatory effects in lung injury (17–19). Antioxidant effects of hypercapnia or acidosis have also been demonstrated in cell culture (20), and because many of these inflammatory processes may be operational in stretch-induced injury, their modulation by CO_2 suggests that elevation of P_{aCO_2} could have protective effects in VALI. Fourth, deliberate elevation of CO_2 —“therapeutic hypercapnia”—protects against primary and secondary ischemia-reperfusion-induced lung injury (17–19), and protective effects have been reported for systemic ischemic injury (21). In addition, two recent studies reported that hypercapnic acidosis protects against stretch-induced lung injury *ex vivo* (22) and *in vivo* (23). However, the clinical role of CO_2 alterations in neonatal practice is unclear (24, 25), and the efficacy of hypercapnic acidosis in *in vivo* models of lung injury associated with surfactant-depletion lung injury is not known.

We used an established *in vivo* rabbit model (saline lung lavage) of surfactant depletion and ventilator-induced lung injury, and used clinically relevant V_t . Our primary aim was to investigate whether therapeutic hypercapnia would improve oxygenation and protect against ventilator-induced lung injury.

METHODS

Male New Zealand White rabbits (Charles River Inc., Quebec, Canada), 2.5 to 3.0 kg, were used in all experiments. All experimental work conformed to the guidelines of the Canadian Council for Animal Care, and was approved by the Animal Care Committee at the Research Institute, Hospital for Sick Children.

Anesthesia and surgical dissection. Premedication was with ketamine (85 mg/kg, intramuscularly). Anesthesia was induced with pentobarbital sodium (15 to 25 mg/kg, i.v.). Incremental bolus doses of pentobarbital (5 mg/kg) were administered as required. Sterile technique was used during all manipulations. A tracheotomy was performed, and a 4-mm (internal diameter) ETT was inserted to a depth of 1 cm and secured in place. Pancuronium (1 mg, i.v.) was administered after depth of anesthesia was confirmed by absence of response to paw compression. Pilot experiments established that anesthetized animals did not exhibit escape behavior in the absence of neuromuscular blockade. The lungs were ventilated using a small animal ventilator (model 683; Harvard Apparatus, MA, U.S.A.) with F_{iO_2} 1.0, rate 22 breaths/min, V_t 9 mL/kg, and 1

cm H_2O PEEP. Under aseptic conditions the right carotid artery was cannulated for arterial pressure measurement and blood sampling. Anesthesia was maintained with pentobarbital (3–6 mg·kg⁻¹·h⁻¹) and muscle relaxation with pancuronium (0.1–0.2 mg·kg⁻¹·h⁻¹), and lactated Ringer’s crystalloid (10–20 mL·kg⁻¹·h⁻¹) was administered by continuous infusion into bilateral marginal ear vein cannulas. Body temperature was maintained (39.0° ± 1.0°C) by use of a heating pack, and confirmed with an indwelling rectal temperature probe.

Saline lavage. Surfactant depletion was induced by lavaging the lungs with warmed sterile saline 0.9% (15 mL/kg, temperature 37°C), using a modification of previously described techniques (26, 27). Saline was infused into the trachea from a height of 30 cm. The abdomen and chest were massaged for 30 s to assist intrapulmonary distribution. The effluent was then drained by gravity. After the first lavage, ventilation was recommenced but with PEEP set to 5 cm H_2O with the other ventilatory variables remaining as before. This lavage procedure was repeated until P_{aO_2} was less than 100 mm Hg. After this target P_{aO_2} was achieved, ventilation was continued for 30 min, and P_{aO_2} was measured again. If the P_{aO_2} had increased to greater than 100 mm Hg by the end of this period, additional lavage was performed.

Lung recruitment. In rabbits in which the P_{aO_2} was sustained at less than 100 mm Hg at 30 min after lavage, a recruitment maneuver was performed. CPAP at 25–30 cm H_2O was administered for 30 s. After this, the ETT was clamped and reconnected to the ventilator circuit with PEEP set at 12.5 cm H_2O . The ETT was unclamped during expiration, and ventilation was continued for 10 min. P_{aO_2} measurement was repeated, and recruitment was considered successful when P_{aO_2} was greater than 200 mm Hg. If P_{aO_2} was less than 200 mm Hg, the recruitment maneuver was repeated. If at this stage P_{aO_2} was less than 200 mm Hg, the animal was excluded from further study.

Group allocation. Animals were then randomly allocated to one of four treatment groups, defined by the type of ventilation strategy (protective *versus* injurious) and F_{iCO_2} , as follows:

- Normocapnia with injurious ventilation (CON_{inj}: F_{iCO_2} 0.00; F_{iO_2} 0.75; balance N_2)
- Therapeutic hypercapnia with injurious ventilation (TH_{inj}: F_{iCO_2} 0.12; F_{iO_2} 0.75; balance N_2)
- Normocapnia with protective ventilation (CON_{pro}: F_{iCO_2} 0.00; F_{iO_2} 0.75; balance N_2)
- Therapeutic hypercapnia with protective ventilation (TH_{pro}: F_{iCO_2} 0.12; F_{iO_2} 0.75; balance N_2)

In addition, Evans blue dye (10 mg/kg, i.v.) was administered after randomization.

Ventilatory strategy. The injurious ventilatory strategy consisted of: V_t 12 mL/kg, PEEP 0 cm H_2O , and a rate of 19 breaths/min. The protective ventilatory strategy consisted of: V_t 5 mL/kg, with PEEP 12.5 cm H_2O and rate 52 breaths/min. Ventilation was continued for 2.5 h (150 min), at which time the animals were killed by exsanguination under anesthesia.

Physiologic variables. Systemic mean arterial pressure, peak airway pressures, and rectal temperature were recorded from a standard monitor (Spacelabs Monitor model 90303B;

Spacelabs Medical Products Ltd., Mississauga, Ontario, Canada) at baseline and every 30 min after randomization.

Blood sampling protocol. Arterial blood samples were measured for pH, P_{CO_2} , and P_{O_2} , using an ABL-300 blood gas analyzer (Radiometer, Copenhagen, Denmark).

Lung mechanics. In all experiments, static inflation compliance was measured at baseline and at completion of the study. Static inflation compliance was determined by injection of incremental 5-mL volumes of 100% O_2 and measurement of pressure attained 4 s after each injection until a total volume of 60 mL was injected. Airway pressure was recorded using a pressure transducer (MP45; Validyne Engineering Corporation, Northridge, CA, U.S.A.) connected to the side port of the ETT adapter, and recorded by an online PC IBM-compatible computer (IPC, Pentium microprocessor, 75 Hz, MS DOS 6.0), using analog-to-digital conversion at a sampling rate of 250 Hz (DT2802A; Data Translocation, Marlboro, MA, U.S.A.) and the software package ANADAT/LABDAT (McGill University, Montreal, Quebec, Canada). An inspiratory pressure-volume curve was then constructed.

Bronchoalveolar lavage. Alveolar-capillary protein permeability was performed using a modification of previously described methodology (28, 29). At the end of the experiment, sternotomy was performed, and the lungs excised and lavaged with 20 mL of saline (0.9%, at 37°C), and 3 mL of BAL fluid was collected. This fluid was divided into two 1.5-mL aliquots and centrifuged. One aliquot was then snap-frozen in liquid nitrogen and stored at -70°C for subsequent cytokine analysis. In the second, the concentration of Evans blue dye in the supernatant was then determined spectrophotometrically by measurement of its absorbance at 620 nm.

Cytokine assay. Analysis of serum and BAL fluid IL-8, GRO, MCP-1, and TNF- α was carried out in duplicate and in a blinded fashion. All were measured with previously described rabbit specific immunoassays (30, 31).

Statistical analysis. Baseline variables and lung permeability were compared with one-way ANOVA. Serial variables were compared using 2-way repeated-measures ANOVA, followed, if significant, by one-way ANOVA within groups over time or among groups at each time. Student-Newman-Keuls or Tukey's tests were used for *post hoc* comparisons. Significance was set at $p < 0.05$. A-a O_2 gradient was calculated using the following formula (32):

$$P(A-a)O_2 = (([R \times PiO_2] + PiCO_2 - PaCO_2 \times [1 - (1-R) \times FiO_2]) / (R + [1-R] \times FiCO_2)) - (PaO_2)$$

Results are expressed as mean \pm SEM. Data were analyzed using SigmaStat (Version 2.0; Jandel Corporation, San Rafael, CA, U.S.A.).

RESULTS

Seven animals failed baseline exclusion criteria, and were not randomized. After *in vivo* surfactant depletion, 28 animals were randomized to one of the following groups:

- Normocapnia with injurious ventilation (high V_t , no PEEP; CON_{inj} ; $n = 8$)

- Therapeutic hypercapnia with injurious ventilation (high V_t , no PEEP; TH_{inj} ; $n = 8$)

- Normocapnia with protective ventilation (low V_t , PEEP; CON_{pro} ; $n = 6$)

- Therapeutic hypercapnia with protective ventilation (low V_t , PEEP; TH_{pro} ; $n = 6$)

Baseline variables. The baseline variables (animal weight, temperature, airway pressure, Hb, and base excess) were comparable in all four experimental groups.

Mortality. Two animals in the TH_{inj} group died near the end of the protocol; data from these animals up to the time of death were recorded and used in the analysis.

Arterial P_{CO_2} and acid base. P_{aCO_2} and arterial pH were comparable in all groups at baseline (Fig. 1). After surfactant depletion, randomization, and alteration of F_{iCO_2} and ventilatory strategy, P_{aCO_2} became most elevated in TH_{inj} (Fig. 1A). The final rank order of P_{aCO_2} was $TH_{inj} > TH_{pro} > CON_{inj} > CON_{pro}$ ($p < 0.05$; Fig. 1A). Arterial pH decreased in all groups except CON_{pro} after institution of the experimental protocol, with the final rank order of pH $TH_{inj} < CON_{inj} < TH_{pro} < CON_{pro}$ ($p < 0.05$; Fig. 1B). There were no differences in plasma HCO_3^- among the groups at baseline. Through the experiment, HCO_3^- decreased in CON_{inj} , remained unchanged in TH_{inj} , and increased in both protective ventilation (CON_{pro} and TH_{pro}) groups (data not shown). These changes likely represent a combination of buffering response (renal retention of bicarbonate with hypercapnia) and lactic acidosis in the injury groups.

Oxygenation. There was no difference in baseline P_{aO_2} among groups (Table 1). After randomization and alteration of F_{iO_2} (from 1.00 to 0.75) and ventilatory strategy, P_{aO_2} fell significantly in all groups, but was significantly higher in CON_{pro} and TH_{pro} compared with CON_{inj} and TH_{inj} . P_{aO_2} remained stable thereafter within all groups for the remainder of the experiment. P_{aO_2} was higher in TH_{pro} versus CON_{pro} at 30 min (Table 1), indicating an effect of hypercapnia that is independent of the ventilation strategy. The rank order of P_{aO_2} at 150 min was $CON_{inj} = TH_{inj} < CON_{pro} = TH_{pro}$ ($p < 0.05$; Table 1). The A-a O_2 gradient was comparable at baseline in all four groups (Fig. 2A). At the end of the experiment (150 min), the rank order of the A-a O_2 gradient was $CON_{inj} = TH_{inj} < CON_{pro} = TH_{pro}$ ($p < 0.05$; Fig. 2A).

Lung permeability. Injurious ventilation worsened alveolar-capillary protein permeability as measured by BAL Evans blue dye concentration, compared with protective ventilation (Fig. 2B), producing a rank order of microvascular leakage of $CON_{inj} = TH_{inj} > CON_{pro} = TH_{pro}$ ($p < 0.05$). Thus, lung permeability was not altered by CO_2 tension.

Pulmonary mechanics. Peak airway pressure (P_{aw}) was comparable in all groups at baseline. The ΔP_{aw} ($P_{aw_{final}} - P_{aw_{30\min}}$) was significantly greater in the two injurious ventilation groups (CON_{inj} , TH_{inj}) versus the two protective groups (CON_{pro} , TH_{pro} ; $p < 0.05$; Table 1), demonstrating a significant impact of ventilatory strategy but no effect of therapeutic hypercapnia. Static inspiratory compliance was comparable in all groups at baseline (Fig. 3A). Static inspiratory compliance decreased significantly over the course of the experiment in both injurious ventilation groups (CON_{inj} , TH_{inj}), but remained




Figure 1. A, rank order of final PaCO₂ was TH_{inj} > TH_{pro} > CON_{inj} > CON_{pro}, **p* < 0.05. B, rank order of final pH was TH_{inj} < CON_{inj} < TH_{pro} < CON_{pro}, **p* < 0.05.

Table 1. Oxygenation and airway pressure

	CON _{INJ}	TH _{INJ}	CON _{PRO}	TH _{PRO}
PaO ₂ (mm Hg)				
Baseline	521.4 ± 12.0	525.2 ± 7.1	497.8 ± 27.9	537.9 ± 13.8
30 min	29.7 ± 0.7*	45.0 ± 2.4*	282.4 ± 32.7*	361.7 ± 24.2*
150 min	34.1 ± 1.7*	38.2 ± 1.6*	282.4 ± 24.9*	325.4 ± 40.2*
Delta peak airway pressure (cm H ₂ O)	2.4 ± 0.4†	3.4 ± 0.5†	0.3 ± 0.2†	0.5 ± 0.3†

Data are mean ± SEM. Delta peak airway pressure is the difference in peak airway pressure (final minus baseline).

* CON_{PRO} = TH_{PRO} > CON_{INJ} = TH_{INJ}; *p* < 0.05.

† CON_{INJ} = TH_{INJ} > CON_{PRO} = TH_{PRO}; *p* < 0.05.

unchanged throughout the experiment in both protective ventilation groups (CON_{pro}, TH_{pro}; Fig. 3B). Thus, the rank order of final static compliance was CON_{inj} = TH_{inj} < CON_{pro} = TH_{pro} (*p* < 0.05), demonstrating an absence of effect of CO₂ tension on final static lung compliance.

Cytokine measurements. Cytokine measurements were obtained from a limited number of animals (*n* = 6 CON_{inj}, TH_{inj}; *n* = 4 CON_{pro}, TH_{pro}). No TNF- α was detected in the BAL from any samples from any of the groups, and there were only minimal levels of TNF- α in the plasma after injurious ventilation (Table 2). After injurious ventilation, therapeutic hypercapnia was associated with significantly lower BAL MCP-1 levels compared with CON_{inj} and comparable to levels seen with protective ventilation (TH_{pro}, CON_{pro}; Fig. 4A). Plasma MCP-1 (Fig. 4B) levels were significantly elevated in all groups. Mean levels of these cytokines were lower in both therapeutic hypercapnic groups (TH_{inj}, TH_{pro}) compared with CON_{inj}, although this was not statistically significant. Plasma IL-8 levels increased significantly in all groups during the course of the experiment (Table 2). Plasma GRO levels were significantly elevated compared with baseline in CON_{inj}, and

were not significantly elevated in other groups (Table 2). Finally, there were no among-group differences in BAL GRO levels (Table 2).

DISCUSSION

The current study demonstrates that therapeutic hypercapnia did not protect against VALI in terms of oxygenation, vascular permeability, or lung mechanics in an *in vivo* surfactant-depletion model.

Ventilation-induced lung injury. The model used in the current study has been used since the 1980s (6, 33), and is well characterized. The histologic injury in this model reflects the deterioration in oxygenation, as well as the impairment of compliance and microvascular leak (6, 33). The model is useful because the high V_t-low PEEP approach combines the effects of tidal stretch, as well as atelectasis, and thus may be a better model of clinical VALI than pure extreme stretch models given that extreme V_t are no longer used.

CO₂ tension and adult respiratory distress syndrome. Limiting V_t during mechanical ventilation in the setting of acute lung injury




Figure 2. A, baseline values for A-aO₂ were similar among groups. The final A-aO₂ was greater in both injurious (TH_{inj}, CON_{inj}) vs both protective (CON_{pro}, TH_{pro}) groups (**p* < 0.05). B, represents BAL absorbance of Evans blue dye, reflecting microvascular leak. The rank order of final values was TH_{inj} = CON_{inj} > CON_{pro} = TH_{pro} (**p* < 0.05).




Figure 3. A, static inflation compliance was comparable among all groups at baseline. B, rank order of final static compliance was TH_{inj} = CON_{inj} < CON_{pro} = TH_{pro} (**p* < 0.05).

results in elevation of PaCO₂ (2). This clinical approach, originally reported in a case series by Wung *et al.* (1), has been extended in a randomized controlled trial to neonates with hypoxemic respiratory failure (4). CO₂ has been traditionally considered to play a passive role in the improved outcome observed with protective ventilatory strategies, and was thus termed permissive hypercap-

nia (2). However, deliberate elevation of CO₂—therapeutic hypercapnia—directly attenuated acute lung injury after free radical generation (19), as well as both primary and secondary ischemia-reperfusion-induced acute lung injury (17–19). In the clinical context, the original reports of deliberate addition of inspired CO₂ were in patients with posttraumatic lung injury (34), in whom the

Table 2. BAL and plasma cytokine levels

	CON _{INJ}	TH _{INJ}	CON _{PRO}	TH _{PRO}
BAL concentration (ng/mL)				
IL-8	5.30 ± 6.40	2.80 ± 2.40	5.10 ± 1.50	5.70 ± 1.20
GRO	0.92 ± 0.26	0.93 ± 0.12	0.82 ± 0.13	0.76 ± 0.04
TNF-α	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Plasma concentration (ng/mL)				
TNF-α				
Baseline	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
30 min	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
150 min	0.50 ± 0.80	0.50 ± 1.20	0.00 ± 0.00	0.00 ± 0.00
IL-8				
Baseline	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
30 min	0.03 ± 0.03	0.00 ± 0.00	0.11 ± 0.11	0.00 ± 0.00
150 min	0.75 ± 0.43†	0.44 ± 0.24†	0.89 ± 0.35†	1.05 ± 0.44†
GRO				
Baseline	0.23 ± 0.08	0.20 ± 0.09	0.26 ± 0.08	0.43 ± 0.17
30 min	0.47 ± 0.15	0.25 ± 0.11	0.43 ± 0.15	0.34 ± 0.18
150 min	0.69 ± 0.08*	0.55 ± 0.13	0.63 ± 0.09	0.37 ± 0.07

Plasma GRO concentration increased as a function of time in the CON_{INJ} group (* $p < 0.05$), but not in any other groups. Plasma IL-8 increased with time in all groups († $p < 0.05$), with no among-group differences. Data are mean ± SEM.




Figure 4. A, BAL MCP-1 concentration was less in TH_{inj} vs CON_{inj}, * $p < 0.05$; values were similar in the other groups. B, plasma MCP-1 increased with time in all groups, † $p < 0.05$, with no among-group differences.

elevated CO₂ appeared to improve cardiac output and oxygenation.

CO₂ and stretch-induced injury. Many of the inflammatory processes described above play a pivotal role in the pathogenesis of VALI. This has led to the suggestion that therapeutic hypercapnia could have protective effects in VALI, a contention supported by recent studies that reported hypercapnic acidosis protects against lung injury induced by severe lung stretch, in both *ex vivo* (22) and *in vivo* (23) models. However, the data in the current study demonstrate that therapeutic hypercapnia does not attenuate indices of lung damage, such as lung permeability and lung compliance in this *in vivo* model of VALI.

Several important experimental differences exist that may help reconcile the contrasting results. The experimental model used by Broccard *et al.* (22) was an *ex vivo* isolated perfused lung preparation, which allows a unique opportunity to measure specific variables (*e.g.* capillary filtration coefficient, microvascular hydrostatic pressure), but which is devoid of the effects of important circulating blood components. The study by Sinclair *et al.* demonstrated protective effects of elevated CO₂, but important differences include the fact that the V_t was extreme (25 mL/kg), the Fio₂ was high (100% inspired O₂), and surfactant depletion was not performed (23); these issues may restrict interpretation. Thus, differences between the current data and other data in the literature may reflect a variety of

model characteristics, including saline lavage, lung volume derecruitment, extremes of V_t , and differences in F_{iO_2} or P_{aO_2} . Finally, the model used in the current study is prone to development of atelectasis (26, 27), and it is possible that whereas CO_2 may attenuate injury caused by tidal stretch—*i.e.* large V_t (22, 23)— CO_2 may be less effective in ameliorating injury caused by atelectasis. This may be important with the increasingly recognized spectrum of atelectasis-associated lung injury (35).

CO_2 and oxygenation. Alteration of CO_2 tension has important effects on gas exchange (16). In a canine oleic acid-induced lung injury model, hypocapnia worsened oxygenation (15), whereas in a bovine pneumonia model, hypercapnia improved P_{aO_2} (36). When the complete formula (32) for calculation of A-a O_2 gradient was used with the current data, there was no effect of CO_2 . However, the complexity of *in vivo* models is such that important interactions, such as the obligate effect of increased cardiac output on intrapulmonary shunt (37), must be taken into account. The lower systemic arterial blood pressure observed in the CON_{inj} group may reflect the complex nature of heart-lung interactions.

Cytokines and VALI. An evolving body of evidence points to a link between high-stretch ventilation and the release of cytokines, such as TNF- α (8–10, 38, 39) and IL-1 β (9, 10, 39). These findings are supported by clinical data demonstrating that high V_t is associated with elevated levels of BAL (3) and plasma IL-6 (3, 5) in patients with adult respiratory distress syndrome. However, three separate *in vivo* studies (40–42) have not been able to demonstrate stretch-induced production of TNF- α , challenging the contention that TNF- α is central to the pathogenesis of VALI. Our findings demonstrate no release of TNF- α into the BAL fluid, and minimal TNF- α release into the plasma with injurious ventilation. These findings cast further doubt on the likelihood of a central pathogenic role for this cytokine in VALI.

A number of studies have reported elevation of IL-8 (or of its functional analog, macrophage inflammatory protein-2) in a variety of different experimental models (40, 43, 44). In the current study, IL-8 is increased to a similar degree in all groups; however, the degree of injury is quite different between protective *versus* injurious ventilatory strategies. Taken together, these data suggest that although IL-8 is released in this model—and other models (40, 43, 44)—the cytokine is unlikely to be uniformly pathogenic in the development of VALI.

Therapeutic hypercapnia and cytokines. Although we detected minimal—or zero—levels of TNF- α resulting from high V_t in the current study, the issue with MCP-1 and GRO is less clear. However, the fact that therapeutic hypercapnia attenuated BAL MCP-1 levels and may have decreased plasma GRO, but did not attenuate the development of severe lung injury in this model, suggests that these cytokines may not be pathogenic in the current model, and casts doubt on an obligatory pathogenic role for these cytokines in VALI. Finally, these findings raise the possibility that in other disease processes in which a pathogenic role for cytokines has been clearly established (*e.g.* sepsis), therapeutic hypercapnia may, by suppressing cytokine production, provide some protection against injury.

Limitations of current findings. There are several issues that limit extrapolation to other contexts. The systemic organ effects of therapeutic hypercapnia were not examined in the current experiments. It is possible that therapeutic hypercapnia-induced attenuation of cytokines may translate to improved systemic organ function; however, the possibility of increased mortality with therapeutic hypercapnia does not support this. It is possible that significant species—or model—variability exists, *e.g.* distribution of pulmonary xanthine oxidase content (45) or species susceptibility to capillary stress failure (46), that could limit application of the findings. However, the current model, or modifications thereof, has been widely studied and has played a major part in the evolution of the literature leading to the clinical recognition of VALI (6, 38, 47). In addition, although designed to represent surfactant depletion as observed in neonates, it is important to note that the animals used in the current study were all adult animals. Finally, the duration of effect may be important, because like virtually all *in vivo* experimental models, the current model uses experimental intervals that are orders of magnitude shorter than the duration of almost any relevant clinical illness. It is possible that with increased duration of injury, different results may have been observed.

CONCLUSIONS

The recognition that lower V_t —without substantial differences in P_{aCO_2} —improves patient outcome from adult respiratory distress syndrome demonstrates the potential that exists to institute protective ventilatory strategies without resorting to significant hypercapnia. This may be critical, because there could be additional beneficial effects of hypercapnia. However, the opposite might be true, and management with what is now accepted permissive hypercapnia might counter the (now-proven) benefits of lessened lung stretch. This work demonstrates that deliberate hypercapnia does not appear to modulate the severity of ventilation-induced lung injury after surfactant depletion. In addition, we were unable to confirm a consistent effect of stretch on release of cytokines. These findings cast doubt on the potential for therapeutic hypercapnia to attenuate VALI, particularly in the context of atelectasis and severe hypoxemia. Additional experimental work will be needed before clinical testing of therapeutic hypercapnia on outcome can be undertaken.

Acknowledgments. The authors are grateful to Drs. A.C. Bryan and J. Lewis for their insightful comments.

REFERENCES

1. Wung JT, James LS, Kilchevsky E, James E 1985 Management of infants with severe respiratory failure and persistence of the fetal circulation, without hyperventilation. *Pediatrics* 76:488–494
2. Hickling KG, Henderson SJ, Jackson R 1990 Low mortality associated with low volume pressure limited ventilation with permissive hypercapnia in severe adult respiratory distress syndrome. *Intensive Care Med* 16:372–377
3. Ranieri VM, Suter PM, Tortorella C, De Tullio R, Dayer JM, Brienza A, Bruno F, Slutsky AS 1999 Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 282:54–61
4. Mariani G, Cifuentes J, Carlo WA 1999 Randomized trial of permissive hypercapnia in preterm infants. *Pediatrics* 104:1082–1088

5. Acute Respiratory Distress Syndrome Network 2000 Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 342:1301–1308
6. Kawano T, Mori S, Cybulsky M, Burger R, Ballin A, Cutz E, Bryan AC 1987 Effect of granulocyte depletion in a ventilated surfactant-depleted lung. *J Appl Physiol* 62:27–33
7. Edmonds JF, Berry E, Wyllie JH 1969 Release of prostaglandins caused by distension of the lungs. *Br J Surg* 56:622–623
8. Imai Y, Kawano T, Miyasaka K, Takata M, Imai T, Okuyama K 1994 Inflammatory chemical mediators during conventional ventilation and during high frequency oscillatory ventilation. *Am J Respir Crit Care Med* 150:1550–1554
9. von Bethmann AN, Brasch F, Nusing R, Vogt K, Volk HD, Muller KM, Wendel A, Uhlig S 1998 Hyperventilation induces release of cytokines from perfused mouse lung. *Am J Respir Crit Care Med* 157:263–272
10. Tremblay L, Valenza F, Ribeiro SP, Li J, Slutsky AS 1997 Injurious ventilatory strategies increase cytokines and c-fos mRNA expression in an isolated rat lung model. *J Clin Invest* 99:944–952
11. Held HD, Boettcher S, Hamann L, Uhlig S 2001 Ventilation-induced chemokine and cytokine release is associated with activation of nuclear factor-kappaB and is blocked by steroids. *Am J Respir Crit Care Med* 163:711–716
12. Webb HH, Tierney DF 1974 Experimental pulmonary edema due to intermittent positive pressure ventilation with high inflation pressures: protection by positive end-expiratory pressure. *Am Rev Respir Dis* 110:556–565
13. Laffey JG, Kavanagh BP 2002 Hypocapnia. *N Engl J Med* 347:43–53
14. Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, Kairalla RA, Deheinzelin D, Munoz C, Oliveira R, Takagaki TY, Carvalho CR 1998 Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. *N Engl J Med* 338:347–354
15. Domino KB, Lu Y, Eisenstein BL, Hlastala MP 1993 Hypocapnia worsens arterial blood oxygenation and increases Va/Q heterogeneity in canine pulmonary edema. *Anesthesiology* 78:91–99
16. Hickling KG, Joyce C 1995 Permissive hypercapnia in ARDS and its effects on tissue oxygenation (Review). *Acta Anaesthesiol Scand* 107:201–208
17. Laffey JG, Tanaka M, Engelberts D, Luo X, Yang S, Tanswell TK, Post M, Lindsay T, Kavanagh BP 2000 Therapeutic hypercapnia reduces pulmonary and systemic injury following in vivo lung reperfusion. *Am J Respir Crit Care Med* 162:2287–2294
18. Strand M, Ikegami M, Jobe AH 2003 Effects of high PCO₂ on ventilated preterm lamb lungs. *Pediatr Res* 53:468–472
19. Shibata K, Cregg N, Engelberts D, Takeuchi A, Fedorko L, Kavanagh BP 1998 Hypercapnic acidosis may attenuate acute lung injury by inhibition of endogenous xanthine oxidase. *Am J Respir Crit Care Med* 158:1578–1584
20. Rehncrona S, Hauge HN, Siesjö BK 1989 Enhancement of iron-catalyzed free radical formation by acidosis in brain homogenates: difference in effect by lactic acid and CO₂. *J Cereb Blood Flow Metab* 9:65–70
21. Vannucci RC, Towfighi J, Heitjan DF, Brucklacher RM 1995 Carbon dioxide protects the perinatal brain from hypoxic-ischemic damage: an experimental study in the immature rat. *Pediatrics* 95:868–874
22. Broccard AF, Hotchkiss JR, Vannay C, Markert M, Sauty A, Feihl F, Schaller M 2001 Protective effects of hypercapnic acidosis on ventilator-induced lung injury. *Am J Respir Crit Care Med* 164:802–806
23. Sinclair SE, Kregenow DA, Lamm WJ, Starr IR, Chi EY, Hlastala MP 2002 Hypercapnic acidosis is protective in an in vivo model of ventilator-induced lung injury. *Am J Respir Crit Care Med* 166:403–408
24. Ambalavanan N, Carlo WA 2001 Hypocapnia and hypercapnia in respiratory management of newborn infants. *Clin Perinatol* 28:517–531
25. Woodgate PG, Davies MW 2001 Permissive hypercapnia for the prevention of morbidity and mortality in mechanically ventilated newborn infants. PG - CD002061 Cochrane Database Syst Rev
26. Lachmann B, Robertson B, Vogel J 1980 In vivo lung lavage as an experimental model of the respiratory distress syndrome. *Acta Anaesthesiol Scand* 24:231–236
27. Murphy D, Cregg N, Tremblay L, Engelberts D, Laffey JG, Slutsky AS, Romaschin A, Kavanagh BP 2000 Adverse ventilator strategy causes pulmonary to systemic translocation of endotoxin. *Am J Resp Crit Care Med* 162:27–33
28. Moxley MA, Baird TL, Corbett JA 2000 Adoptive transfer of acute lung injury. *Am J Physiol Lung Cell Mol Physiol* 279:L985–993
29. Verbrugge SJ, Vazquez de Anda G, Gommers D, Neggers SJ, Sorm V, Bohm SH, Lachmann B 1998 Exogenous surfactant preserves lung function and reduces alveolar Evans blue dye influx in a rat model of ventilation-induced lung injury. *Anesthesiology* 89:467–474
30. Kajikawa O, Johnson MC, 2nd, Goodman RB, Frevert CW, Martin TR 2005 1997 A sensitive immunoassay to detect the alpha-chemokine GRO in rabbit blood and lung fluids. *J Immunol Methods* 135–143
31. Kajikawa O, Goodman RB, Johnson MC, 2nd, Konishi K, Martin TR 1996 Sensitive and specific immunoassays to detect rabbit IL-8 and MCP-1: cytokines that mediate leukocyte recruitment to the lungs. *J Immunol Methods* 197:19–29
32. Tsukimoto K, Arcos JP, Schaffartzik W, Wagner PD, West JB 1990 Effect of common dead space on VA/Q distribution in the dog. *J Appl Physiol* 68:2488–2493
33. McCulloch PR, Forkert PG, Froese AB 1988 Lung volume maintenance prevents lung injury during high frequency oscillatory ventilation in surfactant-deficient rabbits. *Am Rev Respir Dis* 137:1185–1192
34. Trimble C, Smith DE, Rosenthal MH, Fosburg RG 1971 Pathophysiologic role of hypocarbia in post-traumatic pulmonary insufficiency. *Am J Surg* 122:633–638
35. Duggan M, McCaul CL, McNamara PJ, Engelberts D, Ackerley C, Kavanagh BP 2003 Atelectasis causes vascular leak and lethal right ventricular failure in uninjured rat lungs. *Am J Respir Crit Care Med* 167:1633–1640
36. Keenan RJ, Todd TR, DeMajo W, Slutsky AS 1990 Effects of hypercarbia on arterial and alveolar oxygen tensions in a model of gram-negative pneumonia. *J Appl Physiol* 68:1820–1825
37. Cheney FW, Colley PS 1980 The effect of cardiac output on arterial blood oxygenation. *Anesthesiology* 52:496–503
38. Takata M, Abe J, Tanaka H, Kitano Y, Doi S, Kohsaka T, Miyasaka K 1997 Intraalveolar expression of tumor necrosis factor-alpha gene during conventional and high-frequency ventilation. *Am J Respir Crit Care Med* 156:272–279
39. Chiumello D, Pristine G, Slutsky AS 1999 Mechanical ventilation affects local and systemic cytokines in an animal model of acute respiratory distress syndrome. *Am J Respir Crit Care Med* 160:109–116
40. Ricard JD, Dreyfuss D, Saumon G 2001 Production of inflammatory cytokines in ventilator-induced lung injury: a reappraisal. *Am J Respir Crit Care Med* 163:1176–1180
41. Verbrugge SJ, Uhlig S, Neggers SJ, Martin C, Held HD, Haitsma JJ, Lachmann B 1999 Different ventilation strategies affect lung function but do not increase tumor necrosis factor-alpha and prostacyclin production in lavaged rat lungs in vivo. *Anesthesiology* 91:1834–1843
42. Copland IB, Kavanagh BP, Engelberts D, McKertie C, Belik J, Post M 2003 Early changes in lung gene expression due to high tidal volume. *Am J Resp Crit Care Med* (e-published ahead of print - <http://ajrcm.atsjournals.org/cgi/reprint/200208-964OCv1>)
43. Vlahakis NE, Schroeder MA, Limper AH, Hubmayr RD 1999 Stretch induces cytokine release by alveolar epithelial cells in vitro. *Am J Physiol* 277:L167–173
44. Oudin S, Pugin J 2002 Role of MAP kinase activation in interleukin-8 production by human BEAS-2B bronchial epithelial cells submitted to cyclic stretch *Am J Respir Cell Mol Biol* 27:107–114
45. Parks DA, Granger DN 1986 Xanthine oxidase: biochemistry, distribution and physiology. *Acta Physiol Scand Suppl* 548:87–99
46. Mathieu-Costello O, Willford DC, Fu Z, Garden RM, West JB 1995 Pulmonary capillaries are more resistant to stress failure in dogs than in rabbits. *J Appl Physiol* 79:908–917
47. Imai Y, Kawano T, Iwamoto S, Nakagawa S, Takata M, Miyasaka K 1999 Intratracheal anti-tumor necrosis factor-alpha antibody attenuates ventilator-induced lung injury in rabbits. *J Appl Physiol* 87:510–515